Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MGC018 alone and in combination with MGA012 in advanced solid tumors
NCT03729596Phase 2Terminated
- Sponsor
- MacroGenics
- Start
- Nov 2018
- Primary completion
- Mar 2023
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 4
01
Overview
A Phase 2 trial of vobramitamab duocarmazine in solid tumor, metastatic castration-resistant prostate cancer (mCRPC), non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), squamous cell carcinoma of the head and neck (HNSCC), sponsored by MacroGenics. Started Nov 2018; status: terminated.
02
Drugs
vobramitamab duocarmazine
03
Conditions
solid tumormetastatic castration-resistant prostate cancer (mCRPC)non-small cell lung cancer (NSCLC)triple-negative breast cancer (TNBC)squamous cell carcinoma of the head and neck (HNSCC)
Beyond the preview
Go deeper on NCT03729596.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03729596.